Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iscador in Advanced NSCLC
NCT00516022Phase 2Completed
- Sponsor
- Rambam Health Care Campus
- Start
- Apr 2007
- Primary completion
- Mar 2011
- Modality
- Botanical Extract, NPI (Non-pharmacological intervention), Immunomodulator
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of viscum album extract in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Rambam Health Care Campus. Primary endpoints: Quality of Life and Toxicity Profile. Started Apr 2007; status: completed.
02
Drugs
viscum album extract
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00516022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00516022.